Magnetic resonance imaging-based biodistribution of theranostic AGuIX nanoparticles in the NANORAD 2 clinical trial for brain metastases - Takeaways - MDSpire

Magnetic resonance imaging-based biodistribution of theranostic AGuIX nanoparticles in the NANORAD 2 clinical trial for brain metastases

  • By

  • Fabien Boux

  • Alexis Mercier

  • Daniela Talba

  • Jean-Yves Giraud

  • Sandrine Dufort

  • Khalide Seddik

  • Sylvie Grand

  • Mélanie Gataleta

  • Alexandre Leboucher

  • Johan Pietras

  • Olivier De Beaumont

  • Géraldine Le Duc

  • Camille Verry

  • April 4, 2026

  • 0 min

Share

  • 1

    AGuIX nanoparticles serve as both radiosensitizers and MRI contrast agents, enhancing tumor imaging and treatment efficacy in brain metastases.

  • 2

    The NANORAD2 trial evaluates the safety and biodistribution of AGuIX in patients undergoing whole-brain radiotherapy for multiple brain metastases.

  • 3

    MRI assessments in the study provide quantitative insights into AGuIX distribution across brain regions and adjacent organs post-injection.

  • 4

    Patients received three intravenous AGuIX injections, with imaging conducted at strategic timepoints to monitor biodistribution and clearance.

  • 5

    Findings from this study aim to optimize AGuIX administration timing to maximize tumor radiosensitization while minimizing neurocognitive toxicity.

Original Source(s)

Magnetic resonance imaging-based biodistribution of theranostic AGuIX nanoparticles in the NANORAD 2 clinical trial for brain metastases

  • by Fabien Boux, Alexis Mercier, Daniela Talba, Jean-Yves Giraud, Sandrine Dufort, Khalide Seddik, Sylvie Grand, Mélanie Gataleta, Alexandre Leboucher, Johan Pietras, Olivier De Beaumont, Géraldine Le Duc, Camille Verry

  • April 4, 2026

Related Content

Gastric-type endocervical adenocarcinoma with Peutz-Jeghers syndrome: a case report and literature review

Management of toxicities from antibody – drug conjugates in breast cancer

Data requirements of an informative, directive, and preventive mobile health application for gastric cancer